Bruce Booth is a partner and focuses on the discovery and development of novel medicines and therapeutic platforms.
Bruce is currently chairman of Arkuda Therapeutics, AvroBio (NASDAQ:AVRO), Hotspot Therapeutics, Kymera Therapeutics (NASDAQ:KYMR), Nimbus Therapeutics, and Vigil Neuroscience. He also serves on the board of Magenta Therapeutics (NASDAQ:MGTA) and several seed stage companies. He previously served on the boards of past Atlas companies Avila (acquired by Celgene), Lysosomal Therapeutics (acquired by Bial), Padlock (acquired by BMS), Prestwick (acquired by Biovail), Rodin Therapeutics (acquired by Alkermes), Stromedix (acquired by Biogen), and a number of other ventures.
Bruce serves or has served as an advisor in various capacities to Takeda, UCB, the Gates Foundation, and Dana Farber’s Binney Street Capital advisory board. He also serves on the boards of the Pennsylvania State Research Foundation, which helps with technology transfer, and New England Disabled Sports, a charity dedicated to adaptive sports. Bruce blogs about biotech and venture capital topics at LifeSciVC.com, which is syndicated on Forbes.
Prior to joining Atlas in 2005, Bruce was a consultant at McKinsey & Company, as well as an investor for Caxton Health Holdings. As a British Marshall Scholar, Bruce received a D.Phil. (PhD) in molecular immunology from Oxford University. He received a BS in biochemistry, summa cum laude, from The Pennsylvania State University.
Bruce enjoys running, skiing, hiking, and fly fishing. He lives in Wellesley, MA and has three wonderful kids.
What is Bruce Booth's net worth?
The estimated net worth of Bruce Booth is at least $57.71 million as of December 11th, 2025. Dr. Booth owns 685,501 shares of Kymera Therapeutics stock worth more than $57,712,329 as of December 17th. This net worth evaluation does not reflect any other assets that Dr. Booth may own. Additionally, Dr. Booth receives an annual salary of $75,000.00 as Director at Kymera Therapeutics. Learn More about Bruce Booth's net worth.
How old is Bruce Booth?
Dr. Booth is currently 50 years old. There are 4 older executives and no younger executives at Kymera Therapeutics. The oldest executive at Kymera Therapeutics is Ms. Ellen V. Chiniara Esq., J.D., Chief Legal Officer & Corporate Secretary, who is 65 years old. Learn More on Bruce Booth's age.
What is Bruce Booth's salary?
As the Director of Kymera Therapeutics, Inc., Dr. Booth earns $75,000.00 per year. There are 4 executives that earn more than Dr. Booth. The highest earning executive at Kymera Therapeutics is Dr. Nello Mainolfi M.D., Ph.D., Co-Founder, President, CEO & Director, who commands a salary of $1,080,000.00 per year. Learn More on Bruce Booth's salary.
How do I contact Bruce Booth?
Has Bruce Booth been buying or selling shares of Kymera Therapeutics?
In the last ninety days, Bruce Booth has sold $21,698,698.92 in shares of Kymera Therapeutics stock. Most recently, Bruce Booth sold 678 shares of the business's stock in a transaction on Friday, December 12th. The shares were sold at an average price of $91.04, for a transaction totalling $61,725.12. Following the completion of the sale, the director now directly owns 685,393 shares of the company's stock, valued at $62,398,178.72. Learn More on Bruce Booth's trading history.
Who are Kymera Therapeutics' active insiders?
Are insiders buying or selling shares of Kymera Therapeutics?
In the last twelve months, Kymera Therapeutics insiders bought shares 3 times. They purchased a total of 2,978,480 shares worth more than $215,297,266.00. In the last twelve months, insiders at the sold shares 19 times. They sold a total of 659,942 shares worth more than $49,628,701.83. The most recent insider tranaction occured on December, 12th when Director Bruce Booth sold 678 shares worth more than $61,725.12. Insiders at Kymera Therapeutics own 16.0% of the company.
Learn More about insider trades at Kymera Therapeutics. Information on this page was last updated on 12/12/2025.
